← Leaderboards
Keith E Cook
Mc3, Inc.
$7,334,370
Attributed
$7,446,540
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $957.6K · FY2008–25$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,446,540 · 5
By mechanism
R01$6,904,476 · 2
R43$224,341 · 1
R41$162,223 · 1
R03$155,500 · 1
Top collaborators
- David Skoog1 shared
Others in their field
Top investigators on “Respiratory”
- James E. Gern · University Of Wisconsin-Madison$147,090,575
- Richard L Schilsky · University Of Chicago$117,759,216
- Monica M Bertagnolli · Strang Cancer Prevention Center$94,307,968
- Kerry J Kelly · New York City Fire Department$81,924,266
- Mark R Farfel · Hugo W. Moser Res Inst Kennedy Krieger$80,506,780
- John Beigel · Leidos Biomedical Research, Inc.$72,410,171
Research focus
RespiratoryChronic Lung DiseaseTransplantationGasesIn VitroCoagulation ProcessExtracorporeal Membrane OxygenationIn VivoArtificial LungLungBaseLung TransplantationBloodDesignHourMechanical VentilationSheepDevicesResistanceBlood PlateletsBlood FlowInflammationAcutePump
Grant awards (22)
Combined Use of Polycarboxybetaine Coatings with a Selective FXIIa Inhibitor to Create Potent Biomaterial Anticoagulation Without Bleeding During Extracorporeal Life Support$615,042
R01 · FY2025 · HL · contact PI
Combined Use of Polycarboxybetaine Coatings with a Selective FXIIa Inhibitor to Create Potent Biomaterial Anticoagulation Without Bleeding During Extracorporeal Life Support$602,623
R01 · FY2024 · HL · contact PI
Combined Use of Polycarboxybetaine Coatings with a Selective FXIIa Inhibitor to Create Potent Biomaterial Anticoagulation Without Bleeding During Extracorporeal Life Support$74,757
R01 · FY2024 · HL · contact PI
Combined Use of Polycarboxybetaine Coatings with a Selective FXIIa Inhibitor to Create Potent Biomaterial Anticoagulation Without Bleeding During Extracorporeal Life Support$656,020
R01 · FY2023 · HL · contact PI
Combined Use of Polycarboxybetaine Coatings with a Selective FXIIa Inhibitor to Create Potent Biomaterial Anticoagulation Without Bleeding During Extracorporeal Life Support$74,757
R01 · FY2023 · HL · contact PI
Combined Use of Polycarboxybetaine Coatings with a Selective FXIIa Inhibitor to Create Potent Biomaterial Anticoagulation Without Bleeding During Extracorporeal Life Support$681,200
R01 · FY2022 · HL · contact PI
Compliant Thoracic Artificial Lungs$733,235
R01 · FY2017 · HL · contact PI
Pulmonary Assist Device for Destination Therapy$224,341
R43 · FY2017 · HL
Compliant Thoracic Artificial Lungs$639,194
R01 · FY2016 · HL · contact PI
Compliant Thoracic Artificial Lungs$46,293
R01 · FY2016 · HL · contact PI
Compliant Thoracic Artificial Lungs$611,645
R01 · FY2015 · HL · contact PI
Compliant Thoracic Artificial Lungs$447,252
R01 · FY2014 · HL · contact PI
Antibacterial Perfluorocarbon Ventilation to Treat Severe Respiratory Infections$53,426
R03 · FY2013 · AI · contact PI
Antibacterial Perfluorocarbon Ventilation to Treat Severe Respiratory Infections$24,324
R03 · FY2013 · AI · contact PI
Compliant Thoracic Artificial Lungs$356,921
R01 · FY2012 · HL · contact PI
Antibacterial Perfluorocarbon Ventilation to Treat Severe Respiratory Infections$77,750
R03 · FY2012 · AI · contact PI
Compliant Thoracic Artificial Lungs$355,209
R01 · FY2011 · HL · contact PI
Compliant Thoracic Artificial Lungs$369,363
R01 · FY2010 · HL · contact PI
Compliant Thoracic Artificial Lungs$362,842
R01 · FY2009 · HL · contact PI
Compliant Thoracic Artificial Lungs$256,406
R01 · FY2009 · HL · contact PI
Compliant Thoracic Artificial Lungs$21,717
R01 · FY2009 · HL · contact PI
A Compact, Cardiopulmonary Support Device$162,223
R41 · FY2008 · HL · contact PI